title: Cost-effectiveness of 12-dose LTBI regimen improved following advocacy to lower the price of rifapentine.
authors.affiliation: Treatment Action Group, TB/HIV, New York, New York, USA.
authors.forename: Mike
authors.initials: M
authors.lastname: Frick
authors.affiliation: Heartland National TB Center, San Antonio, Texas, USA.
authors.forename: Barbara
authors.initials: B
authors.lastname: Seaworth
authors.affiliation: Treatment Action Group, TB/HIV, New York, New York.
authors.forename: Lindsay
authors.initials: L
authors.lastname: McKenna
authors.affiliation: Community Research Advisors Group, New York, New York, USA.
authors.forename: Taharqa
authors.initials: T
authors.lastname: Elnour
authors.affiliation: Community Research Advisors Group, New York, New York, USA.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Lee
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000191:economics*; D016527:Drug Costs; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000191:economics*; D055985:Latent Tuberculosis / Q000188:drug therapy* / Q000191:economics*; D012293:Rifampin / Q000031:analogs & derivatives*
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin